ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

ClinicalTrials.gov ID: NCT01687608

Public ClinicalTrials.gov record NCT01687608. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B

Study identification

NCT ID
NCT01687608
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Baxalta now part of Shire
Industry
Enrollment
30 participants

Conditions and interventions

Conditions

Interventions

  • AskBio009 Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 10, 2013
Primary completion
Jan 16, 2030
Completion
Jan 16, 2030
Last update posted
Mar 19, 2026

2013 – 2030

United States locations

U.S. sites
15
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
Orthopaedic Hemophilia Treatment Center Los Angeles California 90007
Children's Hospital Los Angeles Los Angeles California 90027
University of California Davis Medical Center Sacramento California 95817
University of California at San Diego Medical Center San Diego California 92103-8651
U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center Aurora Colorado 80045
Emory University Atlanta Georgia 30322
Rush University Medical Center Chicago Illinois 60612
Children's Hospital of Boston Boston Massachusetts 022105
University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute Minneapolis Minnesota 55455
Mount Sinai Medical Center New York New York 10029
The Hemophilia Center, Oregon Health and Science University Portland Oregon 97239
Medical University of South Carolina Charleston South Carolina 29425
Gulf States Hemophilia and Thrombosis Center Houston Texas 77030
Bloodworks Northwest Seattle Washington 98104
BloodCenter of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01687608, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01687608 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →